Research output: Contribution to journal › Article › peer-review
Effect of surfactant coating of Fe3O4 nanoparticles on magnetic dispersive micro-solid phase extraction of tetracyclines from human serum. / Cherkashina, Ksenia; Voznesenskiy, Mikhail; Osmolovskaya, Olga; Vakh, Christina; Bulatov, Andrey.
In: Talanta, Vol. 214, 120861, 01.07.2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Effect of surfactant coating of Fe3O4 nanoparticles on magnetic dispersive micro-solid phase extraction of tetracyclines from human serum
AU - Cherkashina, Ksenia
AU - Voznesenskiy, Mikhail
AU - Osmolovskaya, Olga
AU - Vakh, Christina
AU - Bulatov, Andrey
N1 - Publisher Copyright: © 2020 Elsevier B.V.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - A procedure for separation and preconcentration of tetracyclines from human serum samples involving magnetic dispersive micro-solid phase extraction was proposed. The extraction efficiency of different tetracyclines was improved with the use of the surfactant coated Fe3O4 magnetic nanoparticles. Sorption mechanism was presented, and the potential use of magnetic Fe3O4 nanoparticles coated with different surfactants for tetracyclines adsorption was demonstrated for the first time. The procedure involved nanoparticle floating in a liquid sample phase for analyte extraction followed by elution and determination by high performance liquid chromatography with diode array detection. Influence of the main involved parameters was studied, the system was dimensioned accordingly. The analytical curves were linear in the ranges of 0.25–10 mg L−1 for tetracycline and 0.10–10 mg L−1 for oxytetracycline or doxycycline. Limits of detection were estimated (IUPAC, 3 concept) as 0.08 mg L−1 for tetracycline, and 0.03 mg L−1 for oxytetracycline or doxycycline. The proposed procedure proved to be fast (10 min), simple (two stages), inexpensive (10 mg of nanoparticles) and was applied to human serum samples. Unlike previously synthesized nanoparticles for tetracyclines separation, the surfactant-coated Fe3O4 nanoparticles can be easily prepared with widely available and low-cost reagents. Moreover, elution of the analytes was accomplished in absence of organic solvents by an aqueous chelating agent solution.
AB - A procedure for separation and preconcentration of tetracyclines from human serum samples involving magnetic dispersive micro-solid phase extraction was proposed. The extraction efficiency of different tetracyclines was improved with the use of the surfactant coated Fe3O4 magnetic nanoparticles. Sorption mechanism was presented, and the potential use of magnetic Fe3O4 nanoparticles coated with different surfactants for tetracyclines adsorption was demonstrated for the first time. The procedure involved nanoparticle floating in a liquid sample phase for analyte extraction followed by elution and determination by high performance liquid chromatography with diode array detection. Influence of the main involved parameters was studied, the system was dimensioned accordingly. The analytical curves were linear in the ranges of 0.25–10 mg L−1 for tetracycline and 0.10–10 mg L−1 for oxytetracycline or doxycycline. Limits of detection were estimated (IUPAC, 3 concept) as 0.08 mg L−1 for tetracycline, and 0.03 mg L−1 for oxytetracycline or doxycycline. The proposed procedure proved to be fast (10 min), simple (two stages), inexpensive (10 mg of nanoparticles) and was applied to human serum samples. Unlike previously synthesized nanoparticles for tetracyclines separation, the surfactant-coated Fe3O4 nanoparticles can be easily prepared with widely available and low-cost reagents. Moreover, elution of the analytes was accomplished in absence of organic solvents by an aqueous chelating agent solution.
KW - Surfactant-coated Fe3O4 nanoparticles
KW - Magnetic dispersive micro-solid phase extraction
KW - HPLC-DAD
KW - Tetracyclines
KW - Human serum
KW - Surfactant-coated Fe O nanoparticles
UR - https://www.sciencedirect.com/science/article/abs/pii/S0039914020301521
UR - http://www.scopus.com/inward/record.url?scp=85080082138&partnerID=8YFLogxK
U2 - 10.1016/j.talanta.2020.120861
DO - 10.1016/j.talanta.2020.120861
M3 - Article
VL - 214
JO - Talanta
JF - Talanta
SN - 0039-9140
M1 - 120861
ER -
ID: 52387871